EMJ Hematology 9 [Supplement 6] . 2021

In this issue

Presentations on sickle cell disease (SCD) at the European Hematology Association (EHA) Virtual Congress 2021 spotlighted disease-causing mechanisms, hallmark symptoms, and commonly associated complications. Analysis and discussion focused on traditional therapies such as blood transfusions, haematopoietic stem cell transplantation, and hydroxyurea, whilst also highlighting the promise of a new generation of treatments: gene therapies. Gene addition, gene editing, and gene silencing, though all in the early stages of development, hold exciting potential for patients with SCD.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given